ALIVUSBSEAlivus Life Sciences LtdLowNeutral
Announced Thu, 14 May · 19:48 IST

Enclosed please find herewith intimation with respect to allotment of Equity Shares under the "Employee Stock Option Scheme, 2021".

Capital Market Events View source PDF

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.2%1-day move
₹1066.00
prior close
₹1060.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+0.9+0.4+1.3-1.2-0.4-0.4-0.6-2.5+2.1-6.3-1.7+9.9
Up moveDown movePending
AI summary

Alivus Life Sciences (formerly Glenmark Life Sciences) has allotted 3,100 equity shares of Rs. 2 each to eligible employees who exercised stock options under the ESOS 2021 scheme. The Board approved this at its meeting on May 14, 2026. Following the allotment, the company's paid-up share capital increased marginally from Rs. 24,54,72,696 to Rs. 24,54,78,896, reflecting the issuance of a very small number of shares relative to the total capital base of over 12.27 crore shares.

Likely market impact

The dilution from 3,100 new shares is negligible — less than 0.003% of total shares outstanding — and is unlikely to have any material impact on the stock price or shareholder value.